QTERNMET XR - (2.5MG;1000MG;2.5MG, 5MG;1000MG;2.5MG, 5MG;1000MG;5MG, 10MG;1000MG;5MG ; TABLET,EXTENDED RELEASE)

Generic Name	DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE	**Innovator**	Astrazeneca
Dosage	2.5MG;1000MG;2.5MG, 5MG;1000MG;2.5MG, 5MG;1000MG;5MG, 10MG;1000MG;5MG ; TABLET,EXTENDED RELEASE	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	QTERNMET XR is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a dipeptidyl peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.